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Flexible synthesis of polyfunctionalised
3-ﬂuoropyrroles†
Thomas J. Cogswell,a Craig S. Donaldb and Rodolfo Marquez*a,c
An eﬃcient and selective approach for the synthesis of polyfunctionalised 3-ﬂuoropyrroles has been
developed starting from commercial aldehydes. The methodology is concise, eﬃcient and allows for the
modular and systematic assembly of polysubstituted 3-ﬂuoropyrroles. This synthesis provides an alterna-
tive and highly convergent strategy for the generation of these chemically and biologically important
units.
Introduction
Polyfunctionalised pyrroles are an integral part of medicinal
chemistry, forming the core unit of a number of biologically
active compounds.1–4 Fluorinated polyfunctionalised pyrroles
are particularly interesting due to their useful biological, meta-
bolic, physical and pharmacokinetic properties. Key fluori-
nated pyrroles include compounds such as 1 and 2 which have
been developed as anti-inflammatory and anti-hypertension
agents respectively (Fig. 1).5,6
Thus, it is not surprising that a significant amount of inter-
est has been devoted to the synthesis of fluorinated pyrroles in
recent years.7–9 As such, new flexible and eﬃcient methods for
their syntheses are desired.
Fluorinated α,β-unsaturated lactams were first synthesised
via a ring-closing metathesis approach by Haufe and co-
workers.10 The work was extended by the groups of Rutjes and
Marquez to produce a number of novel fluorinated compounds
(Scheme 1). To date, most work has been centred on the syn-
thesis of 5 and 6-membered lactams with various degrees of
functionalisation.11,12 We feel fluorinated α,β-unsaturated
γ-lactams would be the ideal building block to provide access
to polyfunctionalised fluorinated pyrroles.
Herein, we would like to report a quick, flexible and
modular synthesis of polyfunctionalised fluorinated pyrroles.
The methodology allows for the systematic introduction of
substituents to produce novel polyfunctionalised fluorinated
building blocks (Scheme 1).
Results and discussion
Our initial approach to the synthesis of the pyrrole core began
with the condensation of benzaldehyde 3 with t-butylsulfina-
mide to generate the corresponding imine, which upon vinyla-
tion with vinylmagnesium bromide aﬀorded the desired allylic
amine 4 in excellent yield.13 Reductive amination of amine 4
Fig. 1 Biologically active ﬂuorinated pyrrole examples. Pyrrole 1 has
anti-inﬂammatory activity, while pyrrole 2 is used to alleviate
hypertension.1,2
Scheme 1 Previous work to generate ﬂuorinated δ-lactams via RCM
approach.
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with p-anisaldehyde then produced the PMB protected amine
5 in high yield (Scheme 2).
Coupling of amine 5 with 2-fluoroacrylic acid 6 then pro-
ceeded to produce the desired amide unit 7 in reasonable
yield. Subsequent treatment of diene 7 with Grubbs 2nd gen.
catalyst then aﬀorded the expected α,β-unsaturated lactam 8 in
good yield.12
Rewardingly, alkylation of fluorolactam 8 with methyl-
lithium proceeded cleanly to generate the desired pyrrole unit
9 in excellent yield (Scheme 3).14,15 Mechanistically, we believe
that this aromatisation process takes place through hemi-
aminal formation followed by elimination of water and double
bond isomerisation.15,16
The alkylation–aromatisation methodology was then
expanded by including an array of nucleophiles as to allow for
the selective introduction of substituents at the C2 position of
the C3 fluorinated-pyrrole ring. Thus, a collection of organo-
metallic reagents including DIBAL-H, n-butyllithium, phenyl-
lithium and allylmagnesium bromide were used to generate
the desired substituted pyrroles 10–13 in high yields
(Table 1).14–16
Having demonstrated the ability to incorporate substituents
at the pyrrole C2 position through an alkylation–aromatisation
process, it was decided to explore the ability of our methodo-
logy to incorporate substituents in the other pyrrole positions.
Thus, it was decided to showcase the methodology by gen-
erating a number of C3 fluorinated pyrrole analogues with
diﬀerent N-substituents. Synthetically, the generation of the
new analogues was envisioned as originating through the
incorporation of diﬀerent aldehyde units during the reductive
amination step.
Following this approach, diﬀerent aromatic substitution
patterns were initially explored with the benzyl and 4-bromo-
benzyl derivatives 14a and 14b being cleanly converted to the
RCM precursors 15a and 15b in high yields (Table 2).
The non-aromatic derivative 15c, bearing a cyclohexyl-
methyl group, worked well with yields upwards of 80% for
both steps. N-Methylpyrrole-2-carboxaldehyde was also cleanly
incorporated, yielding the desired diene 15d in good yield over
the sequence.
Ring-closing metathesis was then successfully carried
out in all cases, with isolated yields higher than 80%.17
Scheme 3 Synthesis of ﬂuorinated polysubstituted pyrrole 9.
Table 1 Introduction of diﬀerent nucleophiles (RM) in the synthesis of
tetrasubstituted pyrroles (9–13)
RM Yield
DIBAL-H 78%
PhLi 93%
nBuLi 78%
AllylMgBr 75%
Table 2 Synthesis of ﬂuorinated diene-amides 15a–d
R Yield Yield
74% 14a 74% 15a
81% 14b 71% 15b
82% 14c 86% 15c
71% 14d 58% 15d
Scheme 2 Synthesis of ﬂuorinated α,β-unsaturated lactam 8.
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Gratifyingly, treatment of pyrrolidone compounds 16a–d with
methyllithium under our alkylation–aromatisation method-
ology aﬀorded the desired N-substituted pyrrole derivatives
17a–d in excellent isolated yields (Table 3).
At this point, it was decided to now focus on exploring the
nature and eﬀect of the starting aldehyde on our pyrrole
forming sequence. By changing the identity of the starting
aldehyde, a range of functional groups could be eﬃciently
installed at the C5 position (Table 4).
Electron donating and withdrawing aromatic analogues
were investigated, resulting in good yields of the allylic amine
intermediates 18a–c. Aliphatic aldehydes could also be con-
verted to the corresponding primary amines 18d–e in reason-
able yields.18 Treatment of the crude allylic amines 18a–e
under reductive amination conditions aﬀorded the secondary
amines 19a–e which upon coupling with 2-fluoroacrylic acid 6
generated the desired fluorinated amides 20a–20e in good
yields.
Ring-closing metathesis in all cases proceeded in high
yields (Table 5). However, examples with electron withdrawing
substituents required extended reaction times and higher cata-
lyst loadings (15 mol%) to achieve high yields. Gratifyingly,
treatment of all the pyrrolidone intermediates (21a–21e) under
the methyllithium promoted alkylation–aromatisation con-
ditions yielded the desired fluorinated tetrasubstituted
pyrroles 22a–e in good to excellent yield.
Conclusion
In conclusion, we have developed an eﬃcient and selective
approach for the synthesis of polyfunctionalised 3-fluorinated
pyrroles. The methodology is concise and allows for the
modular synthesis of chemically and biologically important
units.
Experimental
All reactions were performed in oven-dried glassware under an
inert argon atmosphere unless otherwise stated. Tetrahydro-
furan (THF), diethyl ether, toluene and dichloromethane
(DCM) were purified through a solvent purification system.
Petroleum ether refers to the fraction boiling between
40–60 °C. All reagents were used as received, unless otherwise
stated. Solvents were evaporated under reduced pressure at
40 °C unless otherwise stated. IR spectra were recorded as thin
films on NaCl plates using a Fourier Transform spectrometer.
Only significant absorptions (νmax) are reported in wavenum-
bers (cm−1). Proton magnetic resonance spectra (1H NMR)
were recorded at either 400 or 500 MHz. Fluorine magnetic
Table 4 Synthesis of ﬂuorinated amides 20a–e
R Yield Yield Yield
4-MeOC6H4 71% 18a 79% 19a 60% 20a
4-CF3C6H4 61% 18b 80% 19b 45% 20b
4-BrC6H4 75% 18c 84% 19c 62% 20c
Cyclohexyl 50% 18d 70% 19d 76% 20d
PhCH2CH2 58% 18e 88% 19e 75% 20e
Table 3 Synthesis of ﬂuorinated pyrroles 17a–d
R Yield Yield
98% 16a 86% 17a
96% 16b 83% 17b
92% 16c 84% 17c
81% 16d 75% 17d
Table 5 Synthesis of ﬂuorinated pyrroles 22a–d
R Yield Yield
71% 21a 88% 22a
88% 21b 73% 22b
94% 21c 78% 22c
95% 21d 92% 22d
96% 21e 74% 22e
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resonance spectra (19F NMR) were recorded at either 377 or
470 MHz. Carbon magnetic resonance spectra (13C NMR) were
recorded at either 100 or 125 MHz. Chemical shifts (δ) are
reported in parts per million (ppm) and are referenced to the
residual solvent peak. The order of citation in parentheses is
(1) number of equivalent nuclei (by integration), (2) multi-
plicity (s = singlet, d = doublet, t = triplet, q = quartet, quint =
quintet, sext = sextet, sept = septet, m = multiplet, b = broad),
(3) and coupling constant ( J) quoted in Hertz to the nearest
0.1 Hz. High resolution mass spectra were obtained by electro-
spray (EI) chemical ionisation (CI) mass spectrometery operat-
ing at a resolution of 15 000 full widths at half height. Flash
chromatography was performed using silica gel (40–63 micron)
as the stationary phase. TLC was performed on aluminium
sheets pre-coated with silica (Silica Gel 60 F254) unless other-
wise stated. The plates were visualised by the quenching of UV
fluorescence (λmax 254 nm) and/or by staining with either
anisaldehyde, potassium permanganate, iodine or cerium
ammonium molybdate followed by heating.
General procedure I
A solution of the diene (1 eq.) in toluene (0.005 g ml−1) and
was heated to 100 °C. Grubbs 2nd generation catalyst was
added in portions and the reaction was stirred until com-
pletion as indicated by TLC analysis. The reaction was cooled
down to room temperature, the solvent was removed under
reduced pressure and the crude material was purified by flash
column chromatography.
General procedure II
α,β-Unsaturated lactam (1 eq.) was dissolved in diethyl ether
(5 mL) and cooled to 0 °C. Methyllithium (1.1 eq.) was added
dropwise and the mixture was stirred for 1 h. Following this
time, the reaction was quenched with H2O (10 mL), extracted
with diethyl ether (3 × 10 mL), dried (Na2SO4) and evaporated
in vacuo. The crude residue was purified by flash column
chromatography.
3-Fluoro-1-[(4′-methoxyphenyl)methyl]-5-phenyl-2,5-dihydro-
1H-pyrrol-2-one, 8. Dialkene 7 (270 mg, 0.84 mmol) was
treated with 7.5 mol% Grubbs 2nd generation catalyst as
described in General procedure I. The crude product was puri-
fied by flash column chromatography (0–15% EtOAc in pet-
roleum ether) to yield the desired α,β-unsaturated lactam 8
(210 mg, 0.71 mmol, 83%) as a pale yellow oil. 1H NMR
(CDCl3, 400 MHz) δ: 7.50–7.33 (3H, m), 7.20–7.09 (2H, m), 7.06
(2H, JH = 8.6 Hz), 6.85 (2H, d, JH = 8.6 Hz), 6.26 (1H, d, JH =
1.6 Hz), 5.12 (1H, d, JH = 14.8 Hz), 4.78 (1H, dd, JF = 6.0 Hz,
JH = 2.4 Hz), 3.82 (3H, m), 3.58 (1H, JH = 14.8 Hz).
19F NMR
(CDCl3, 470 MHz) δ: −138.5. 13C NMR (CDCl3, 125 MHz)
δ: 163.0 (d, JF = 31.2 Hz), 159.2, 152.3 (d, JF = 279.6 Hz), 133.9
(d, JF = 2.1 Hz), 129.8 (2C), 129.3 (2C), 129.2, 128.6, 127.6 (2C),
118.4 (d, JF = 4.4 Hz), 114.2 (2C), 59.1 (d, JF = 5.7 Hz), 55.3,
43.5. m/z [EI (+ve)] 297.2 [M]+, HRMS found [M]+ 297.1164,
C18H16FNO2 requires 297.1165. IR (thin film) vmax = 2355,
1710, 1666, 1514, 1247 cm−1.
3-Fluoro-1-[(4′-methoxyphenyl)methyl]-2-methyl-5-phenyl-
1H-pyrrole, 9. α,β-Unsaturated lactam 8 (36 mg, 0.12 mmol)
was reacted with methyl lithium (83 μL, 0.13 mmol, 1.6 M in
diethyl ether) following General procedure II. The product was
purified by flash column chromatography (0–2.5% diethyl
ether in petroleum ether) to yield the pyrrole 9 (30 mg,
0.1 mmol, 86%) as a white solid. 1H NMR (CDCl3, 400 MHz) δ:
7.35–7.13 (5H, m), 6.78–6.76 (4H, m), 5.96 (1H, s), 4.93 (2H, s),
3.72 (3H, s), 1.98 (3H, d, JF = 1.6 Hz).
19F NMR (CDCl3,
470 MHz) δ: −169.4. 13C NMR (CDCl3, 125 MHz) δ: 158.7, 149.2
(d, JF = 235.6 Hz), 132.9, 130.6, 130.1 (d, JF = 6.9 Hz), 128.8
(2C), 128.5 (2C), 127.1, 126.7 (2C), 114.2 (2C), 112.5 (d, JF =
24.3 Hz), 96.4 (d, JF = 16.4 Hz), 55.3, 47.2, 8.2. m/z [EI (+ve)]
295.2 [M]+, HRMS found [M]+ 295.1373 C19H18FNO requires
295.1372. IR (thin film) vmax = 2928, 2359, 1614, 1599, 1512,
1352, 1249, 1174 cm−1. m.p. 73–75 °C.
4-Fluoro-1-[(4′-methoxyphenyl)methyl]-2-phenyl-1H-pyrrole,
10. α,β-Unsaturated lactam 8 (40 mg, 0.13 mmol) was dis-
solved in CH2Cl2 (4 mL) and cooled to −78 °C. Diisobutyl-
aluminium hydride (0.41 mL, 0.41 mmol, 1 M in hexanes) was
added dropwise and the mixture was stirred for 16 h. Follow-
ing this time, the reaction was quenched with H2O (10 mL),
extracted with diethyl ether (3 × 10 mL), dried (Na2SO4) and
evaporated in vacuo. The crude residue was purified be flash
column chromatography (0–2.5% diethyl ether in petroleum
ether) to yield the pyrrole 10 (30 mg, 0.11 mmol, 85%) as a
yellow oil. 1H NMR (CDCl3, 400 MHz) δ: 7.40–7.32 (5H, m),
6.98 (2H, d, JH = 8.7 Hz), 6.86 (2H, d, JH = 8.7 Hz), 6.46 (1H, dd,
JF = 3.2 Hz, JH = 2.0 Hz), 6.04 (1H, d, JF = 2.4 Hz), 4.99 (2H, s),
3.82 (3H, s). 19F NMR (CDCl3, 470 MHz) δ: −165.4. 13C NMR
(CDCl3, 125 MHz) δ: 159.0, 152.0 (d, JF = 239.1 Hz), 132.5 (d,
JF = 1.6 Hz), 131.8 (d, JF = 6.4 Hz), 130.2, 129.0 (2C), 128.5 (2C),
127.9 (2C), 127.5, 114.1 (2C) 105.5 (d, JF = 27.3 Hz), 97.1 (d, JF =
16.4 Hz), 55.3, 50.2. m/z [EI (+ve)] 281.1 [M]+, HRMS found
[M]+ 281.1215, C18H16FNO requires 281.1216. IR (thin film)
vmax = 2956, 2837, 1701, 1612, 1512, 1247, 1176 cm
−1.
3-Fluoro-1-[(4′-methoxyphenyl)methyl]-2,5-diphenyl-1H-pyrrole,
11. α,β-Unsaturated lactam 8 (45 mg, 0.15 mmol) was dis-
solved in diethyl ether (5 mL) and cooled to 0 °C. Phenyl-
lithium (87 μL, 0.16 mmol, 1.9 M in di-n-butyl ether) was
added dropwise and the mixture was stirred for 1 h. Following
this time, the reaction was quenched with H2O (10 mL),
extracted with diethyl ether (3 × 10 mL), dried (Na2SO4) and
evaporated in vacuo. The crude residue was purified be flash
column chromatography (0–2.5% diethyl ether in petroleum
ether) to yield the pyrrole 11 (50 mg, 0.14 mmol, 93%) as a
white solid. 1H NMR (CDCl3, 400 MHz) δ: 7.39–7.36 (7H, m),
7.35–7.37 (3H, m), 6.66 (2H, d, JH = 8.8 Hz), 6.55 (2H, d, JH =
8.8 Hz), 6.17 (1H, br s), 5.10 (2H, s), 3.74 (3H, s). 19F NMR
(CDCl3, 470 MHz) δ: −165.3. 13C NMR (CDCl3, 125 MHz) δ:
158.5, 149.6 (d, JF = 242.5 Hz), 133.0 (d, JF = 7.1 Hz), 132.9 (d,
JF = 1.8 Hz), 130.8, 129.9 (d, JF = 3.3 Hz), 129.5, 129.1 (2C),
128.5 (2C), 128.5 (2C), 127.5, 127.3 (2C), 127.2, 119.1 (d, JF =
21.0 Hz), 113.7 (2C), 98.4 (d, JF = 16.6 Hz), 55.2, 48.3. m/z
[EI (+ve)] 357.0 [M]+, HRMS found [M]+ 357.1531,
C24H20FNO requires 357.1529. IR (thin film) vmax = 3063,
Paper Organic & Biomolecular Chemistry
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2955, 2835, 1610, 1512, 1492, 1435, 1247, 1176 cm−1. m.p.
84–86 °C.
2-Butyl-3-fluoro-1-[(4′-methoxyphenyl)methyl]-5-phenyl-1H-
pyrrole, 12. α,β-Unsaturated lactam 8 (38 mg, 0.13 mmol) was
dissolved in diethyl ether (5 mL) and cooled to 0 °C. n-Butyl-
lithium (54 μL, 0.13 mmol, 2.5 M in hexanes) was added drop-
wise and the mixture was stirred for 1 h. Following this time,
the reaction was quenched with H2O (10 mL), extracted with
diethyl ether (3 × 10 mL), dried (Na2SO4) and evaporated
in vacuo. The crude residue was purified by flash column
chromatography (0–2.5% diethyl ether in petroleum ether) to
yield the pyrrole 12 (34 mg, 0.10 mmol, 78%) as a white solid.
1H NMR (CDCl3, 400 MHz) δ: 7.22–7.14 (5H, m), 6.74 (4H, m),
5.95 (1H, s), 4.94 (2H, s), 3.71 (3H, s), 2.37 (2H, t, JH = 7.6 Hz),
1.43–1.34 (2H, m), 1.25–1.18 (2H, m), 0.78 (3H, t, JH = 7.3 Hz).
19F NMR (CDCl3, 470 MHz) δ: −168.0. 13C NMR (CDCl3,
125 MHz) δ: 158.7, 149.5 (d, JF = 236.1 Hz), 133.0, 131.0, 130.0
(d, JF = 7.0 Hz), 128.9 (2C), 128.4 (2C), 127.1, 126.7 (2C), 117.0
(d, JF = 23.5 Hz), 114.1 (2C), 96.7 (d, JF = 16.6 Hz), 55.3, 47.1,
31.3 (d, JF = 2.0 Hz), 23.1 (d, JF = 2.6 Hz), 22.4, 13.8. m/z
[EI (+ve)] 337.2 [M]+, HRMS found [M]+ 337.1840, C22H24FNO
requires 337.1842. IR (thin film) vmax = 2956, 2929, 2858, 1612,
1595, 1512, 1464, 1249 cm−1. m.p. 32–34 °C.
3-Fluoro-1-[(4″-methoxyphenyl)methyl]-5-phenyl-2-(prop-2′-
en-1′-yl)-1H-pyrrole, 13. α,β-Unsaturated lactam 8 (41 mg,
0.14 mmol) was dissolved in diethyl ether (5 mL) and cooled
to 0 °C. Allylmagnesium bromide (0.21 mL, 0.21 mmol, 1 M in
Et2O) was added dropwise and the mixture was stirred for
1.5 h. Following this time, the reaction was quenched with
H2O (10 mL), extracted with diethyl ether (3 × 10 mL), dried
(Na2SO4) and evaporated in vacuo. The crude residue was puri-
fied be flash column chromatography (0–2.5% diethyl ether in
petroleum ether) to yield the pyrrole 13 (34 mg, 0.11 mmol,
75%) as a white solid. 1H NMR (CDCl3, 400 MHz) δ: 7.30–7.12
(5H, m), 6.75 (4H, m), 5.98 (1H, s), 5.76 (1H, ddt, JH = 16.1,
10.1, 6.0 Hz), 5.00–4.84 (4H, m), 3.71 (3H, s, OCH3), 3.12 (2H,
dd, JH = 5.9, 0.8 Hz).
19F NMR (CDCl3, 470 MHz) δ: −168.0. 13C
NMR (CDCl3, 125 MHz) δ: 158.7, 149.5 (d, JF = 237.3 Hz), 135.3,
132.8, 130.8, 130.7, 128.9 (2C), 128.5 (2C), 127.2, 126.7 (2C),
115.4, 114.2 (2C), 113.9 (d, JF = 23.5 Hz), 96.6 (d, JF = 16.3 Hz),
55.3, 47.1, 27.5 (d, JF = 2.1 Hz). m/z [EI (+ve)] 321.1 [M]
+, HRMS
found [M]+ 321.1526, C21H20FNO requires 321.1529. IR (thin
film) vmax = 2931, 1612, 1595, 1512, 1354, 1247, 1174 cm
−1.
m.p. 30–32 °C.
1-Benzyl-3-fluoro-5-phenyl-2,5-dihydro-1H-pyrrol-2-one, 16a.
Dialkene 15a (110 mg, 0.36 mmol) was treated with 7.5 mol%
Grubbs 2nd generation catalyst as described in General pro-
cedure I. The crude product was purified by flash column
chromatography (0–10% EtOAc in petroleum ether) to yield the
desired α,β-unsaturated lactam 16a (100 mg, 0.35 mmol, 98%)
as a pale yellow oil. 1H NMR (CDCl3, 400 MHz) δ: 7.35–7.29
(3H, m), 7.26–7.20 (3H, m), 7.05–7.01 (4H, m), 6.19 (1H, d, JH =
1.9 Hz), 5.08 (1H, d, JH = 15.0 Hz), 4.70 (1H, dd, JF = 5.8 Hz,
JH = 2.3 Hz), 3.53 (1H, d, JH = 15.0 Hz).
19F NMR (CDCl3,
470 MHz) δ: −138.6. 13C NMR (CDCl3, 125 MHz) δ: 163.0 (d,
JF = 31.3 Hz), 152.4 (d, JF = 279.5 Hz), 136.5, 133.8, 129.3 (2C),
129.2, 128.8 (2C), 128.4 (2C), 127.8, 127.6 (2C), 118.5 (d, JF =
4.4 Hz), 59.3 (d, JF = 5.7 Hz), 44.1. m/z [ESI (+ve)] 290.1 [M +
Na]+, HRMS found [M + Na]+ 290.0943, C17H14FNONa requires
290.0940. IR (thin film) vmax = 3063, 1710, 1666, 1456, 1220,
1186 cm−1.
3-Fluoro-1-[(4′-bromophenyl)methyl]-5-phenyl-2,5-dihydro-
1H-pyrrol-2-one, 16b. Dialkene 15b (120 mg, 0.31 mmol) was
treated with 7.5 mol% Grubbs 2nd generation catalyst as
described in General procedure I. The crude product was
purified by flash column chromatography (0–5% EtOAc in pet-
roleum ether) to yield the desired α,β-unsaturated lactam 16b
(100 mg, 0.29 mmol, 96%) as a pale yellow oil. 1H NMR
(CDCl3, 400 MHz) δ: 7.36 (2H, d, JH = 8.3 Hz), 7.34–7.28 (3H,
m), 7.03–7.00 (2H, m), 6.91 (2H, d, JH = 8.3 Hz), 6.21 (1H, d,
JH = 2.0 Hz), 4.98 (1H, JH = 15.0 Hz), 4.69 (1H, dd, JF = 5.8 Hz,
JH = 2.2 Hz), 3.54 (1H, JH = 15.0 Hz).
19F NMR (CDCl3,
470 MHz) δ: −138.5. 13C NMR (CDCl3, 125 MHz) δ: 163.0 (d,
JF = 31.3 Hz), 152.3 (d, JF = 279.8 Hz), 135.5, 133.6 (d, JF =
2.2 Hz), 132.0 (2C), 130.1 (2C), 129.4 (2C), 129.3, 127.5 (2C),
121.9, 118.6 (d, JF = 4.4 Hz), 59.4 (d, JF = 5.6 Hz), 43.6. m/z
[EI (+ve)] 344.9 [M]+, HRMS found [M]+ 345.0167,
C17H13BrFNO requires 345.0165. IR (thin film) vmax = 2960,
1708, 1666, 1489, 1404, 1220, 1012 cm−1.
3-Fluoro-1-(cyclohexylmethyl)-5-phenyl-2,5-dihydro-1H-pyrrol-
2-one, 16c. Dialkene 15c (150 mg, 0.5 mmol) was treated with
7.5 mol% Grubbs 2nd generation catalyst as described in
General procedure I. The crude product was purified by flash
column chromatography (0–7.5% EtOAc in petroleum ether) to
yield the desired α,β-unsaturated lactam 16c (130 mg,
0.46 mmol, 92%) as a pale yellow oil. 1H NMR (CDCl3,
500 MHz) δ: 7.37–7.22 (3H, m), 7.09–7.07 (2H, m), 6.20 (1H, d,
JH = 1.5 Hz), 4.90 (1H, dd, JF = 5.5 Hz, JH = 2.0 Hz), 3.48 (1H,
dd, JH = 14.0, 8.7 Hz), 2.46 (1H, dd, JH = 14.0, 6.0 Hz),
1.63–1.58 (2H, m), 1.40–1.43 (3H, m), 1.09–1.04 (3H, m),
0.87–0.79 (3H, m). 19F NMR (CDCl3, 470 MHz) δ: −138.4. 13C
NMR (CDCl3, 125 MHz) δ: 163.3 (d, JF = 31.0 Hz), 152.6 (d, JF =
279.3 Hz), 134.2, 129.3 (2C), 129.1, 127.4 (2C), 117.9 (d, JF =
4.4 Hz), 60.7 (d, JF = 5.9 Hz), 46.6, 37.0, 30.9, 30.4, 26.3, 25.7,
25.6. m/z [EI (+ve)] 273.2 [M]+, HRMS found [M]+ 273.1528,
C17H20FNO requires 273.1529. IR (thin film) vmax = 2922, 2852,
1703, 1666, 1448, 1220, 1116 cm−1.
3-Fluoro-1-[(1′-methyl-1H-pyrrol-2′-yl)methyl]-5-phenyl-2,5-
dihydro-1H-pyrrol-2-one, 16d. Dialkene 15d (80 mg,
0.27 mmol) was treated with 7.5 mol% Grubbs 2nd generation
catalyst as described in General procedure I. The crude
product was purified by flash column chromatography (0–5%
EtOAc in petroleum ether) to yield the desired α,β-unsaturated
lactam 16d (60 mg, 0.22 mmol, 81%) as a pale yellow solid. 1H
NMR (CDCl3, 400 MHz) δ: 7.45–7.27 (3H, m), 7.09–7.06 (2H,
m), 6.51 (1H, appt t, JH = 2.4 Hz), 6.18 (1H, d, JH = 2.0 Hz), 5.95
(1H, dd, JH = 3.6, 2.8 Hz), 5.78 (1H, dd, JH = 3.6, 2.0 Hz), 4.99
(1H, d, JH = 15.5 Hz), 4.74 (1H, dd, JF = 5.9 Hz, JH = 2.3 Hz),
3.60 (1H, d, JH = 15.5 Hz), 3.48 (3H, s).
19F NMR (CDCl3,
470 MHz) δ: −138.7. 13C NMR (CDCl3, 125 MHz) δ: 162.4 (d,
JF = 31.3 Hz), 151.9 (d, JF = 279.8 Hz), 133.7, 129.3 (2C), 129.1,
127.6 (2C), 126.8, 123.3, 118.8 (d, JF = 4.2 Hz), 110.3, 106.9,
Organic & Biomolecular Chemistry Paper
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58.9 (d, JF = 5.5 Hz), 35.4, 34.1. m/z [EI (+ve)] 270.1 [M]
+, HRMS
found [M]+ 270.1170, C16H15FN2O requires 270.1168. IR (thin
film) vmax = 2960, 2359, 1716, 1666, 1417, 1217 cm
−1. m.p.
92–94 °C.
1-Benzyl-3-fluoro-2-methyl-5-phenyl-1H-pyrrole, 17a. α,β-Un-
saturated lactam 16a (33 mg, 0.13 mmol) was reacted with
methyllithium (100 μL, 0.14 mmol, 1.4 M in diethyl ether) fol-
lowing General procedure II. The product was purified by flash
column chromatography (0–2.5% diethyl ether in petroleum
ether) to yield the pyrrole 17a (29 mg, 0.11 mmol, 86%) as a
white solid. 1H NMR (CDCl3, 400 MHz) δ: 7.30–7.09 (8H, m),
6.87–6.84 (2H, m), 5.98 (1H, s), 4.99 (2H, s), 1.97 (3H, d, JF =
1.6 Hz). 19F NMR (CDCl3, 470 MHz) δ: −169.3. 13C NMR
(CDCl3, 125 MHz) δ: 149.2 (d, JF = 235.6 Hz), 138.6, 132.8,
130.2 (d, JF = 3.3 Hz), 128.8 (2C), 128.8 (2C), 128.5 (2C), 127.2,
127.1, 125.6 (2C), 112.6 (d, JF = 24.4 Hz), 96.5 (d, JF = 16.5 Hz),
47.8, 8.2. m/z [EI (+ve)] 265.1 [M]+, HRMS found [M]+ 265.1269,
C18H16FN requires 265.1267. IR (thin film) vmax = 2924, 1662,
1599, 1452, 1352, 1118 cm−1. m.p. 44–46 °C.
1-[(4′-Bromophenyl)methyl]-3-fluoro-2-methyl-5-phenyl-1H-
pyrrole, 17b. α,β-Unsaturated lactam 16b (38 mg, 0.11 mmol)
was reacted with methyllithium (74 μL, 0.12 mmol, 1.6 M in
diethyl ether) following General procedure II. The product was
purified by flash column chromatography (0–2.5% diethyl
ether in petroleum ether) to yield the pyrrole 17b (31 mg,
0.09 mmol, 83%) as a white solid. 1H NMR (CDCl3, 400 MHz)
δ: 7.36 (2H, d, JH = 8.6 Hz), 7.27–7.14 (5H, m), 6.72 (2H, d, JH =
8.6 Hz), 5.98 (1H, s), 4.93 (2H, s), 1.97 (3H, d, JF = 1.6 Hz).
19F
NMR (CDCl3, 470 MHz) δ: −168.8. 13C NMR (CDCl3, 125 MHz)
δ: 149.3 (d, JF = 236.2 Hz), 137.7, 132.6, 131.9 (2C), 130.2 (d,
JF = 6.8 Hz), 128.8 (2C), 128.6 (2C), 127.3 (2C), 127.3, 121.0,
112.4 (d, JF = 24.4 Hz), 96.8 (d, JF = 16.5 Hz), 47.2, 8.1 (d, JF =
2.1 Hz). m/z [EI (+ve)] 343.1 [M]+, HRMS found [M]+ 343.0367,
C18H15FNBr requires 343.0372. IR (thin film) vmax = 2924,
1680, 1599, 1489, 1363, 1072, 1010 cm−1. m.p. 98–100 °C.
1-(Cyclohexylmethyl)-3-fluoro-2-methyl-5-phenyl-1H-pyrrole,
17c. α,β-Unsaturated lactam 16c (36 mg, 0.13 mmol) was
reacted with methyllithium (91 μL, 0.15 mmol, 1.6 M in
diethyl ether) following General procedure II. The product was
purified by flash column chromatography (0–2.5% diethyl
ether in petroleum ether) to yield the pyrrole 17c (29 mg,
0.11 mmol, 84%) as a white solid. 1H NMR (CDCl3, 500 MHz)
δ: 7.31–7.28 (2H, m), 7.25–7.20 (3H, m), 5.81 (1H, s), 3.66 (2H,
d, JH = 7.0 Hz), 2.17 (3H, d, JF = 1.6 Hz), 1.50–1.45 (3H, m),
1.28–1.23 (3H, m), 0.98–0.88 (3H, m), 0.56–0.49 (2H, m). 19F
NMR (CDCl3, 470 MHz) δ: −170.1. 13C NMR (CDCl3, 125 MHz)
δ: 149.1 (d, JF = 235.0 Hz), 133.9, 130.0 (d, JF = 7.2 Hz), 128.3
(2C), 128.3 (2C), 126.8, 112.2 (d, JF = 23.8 Hz), 96.3 (d, JF =
16.3 Hz), 50.2, 39.2, 30.4 (2C), 26.2, 25.7 (2C), 8.5 (d, JF =
1.9 Hz). m/z [EI (+ve)] 271.1 [M]+, HRMS found [M]+ 271.1733,
C18H22FN requires 271.1736. IR (thin film) vmax = 2926, 2852,
1597, 1450, 1348, 1112 cm−1. m.p. 73–75 °C.
3-Fluoro-2-methyl-1-[(1′-methyl-1H-pyrrole-2′-yl)methyl]-5-
phenyl-1H-pyrrole, 17d. α,β-Unsaturated lactam 16d (31 mg,
0.12 mmol) was reacted with methyllithium (79 μL,
0.13 mmol, 1.6 M in diethyl ether) following General pro-
cedure II. The product was purified by flash column chromato-
graphy (0–2.5% diethyl ether in petroleum ether) to yield the
pyrrole 17d (23 mg, 0.09 mmol, 75%) as a white solid. 1H NMR
(CDCl3, 400 MHz) δ: 7.28–7.23 (2H, m), 7.23–7.19 (3H, m), 6.46
(1H, appt t, JH = 2.5 Hz), 5.95 (1H, appt t, JH = 3.5 Hz), 5.92
(1H, s), 5.70–5.69 (1H, m), 4.88 (2H, s), 3.26 (3H, s), 2.03 (3H,
d, JF = 1.6 Hz).
19F NMR (CDCl3, 470 MHz) δ: −169.5. 13C NMR
(CDCl3, 125 MHz) δ: 149.2 (d, JF = 235.4 Hz), 133.0, 129.9 (d,
JF = 6.9 Hz), 128.8 (3C), 128.5 (2C), 127.1, 122.3, 112.9 (d, JF =
24.6 Hz), 107.9, 107.1, 96.4 (d, JF = 16.5 Hz), 41.6, 33.7, 8.2. m/z
[EI (+ve)] 268.1 [M]+, HRMS found [M]+ 268.1380, C17H17FN2
requires 268.1376. IR (thin film) vmax = 2922, 1705, 1599, 1469,
1361, 1301, 1089 cm−1. m.p. 69–71 °C.
1-Benzyl-3-fluoro-5-(4′-methoxyphenyl)-2,5-dihydro-1H-pyrrol-
2-one, 21a. Dialkene 20a (100 mg, 0.31 mmol) was treated
with 7.5 mol% Grubbs 2nd generation catalyst as described in
General procedure I. The crude product was purified by flash
column chromatography (0–10% EtOAc in petroleum ether) to
yield the desired α,β-unsaturated lactam 21a (70 mg,
0.22 mmol, 71%) as a white solid. 1H NMR (CDCl3, 400 MHz)
δ: 7.35–7.29 (3H, m), 7.14–7.13 (2H, m), 7.03 (2H, d, JH =
8.7 Hz), 6.93 (2H, d, JH = 8.7 Hz), 6.25 (1H, d, JH = 1.6 Hz), 5.15
(1H, d, JH = 15.0 Hz), 4.75 (1H, dd, JF = 5.8 Hz, JH = 2.1 Hz),
3.85 (3H, s), 3.61 (1H, d, JH = 15.0 Hz).
19F NMR (CDCl3,
470 MHz) δ: −138.7. 13C NMR (CDCl3, 125 MHz) δ: 162.9 (d,
JF = 31.3 Hz), 160.3, 152.3 (d, JF = 279.3 Hz), 136.7, 128.9 (2C),
128.8 (2C), 128.4 (2C), 127.8, 125.4 (d, JF = 2.1 Hz), 118.5 (d,
JF = 4.0 Hz), 114.6 (2C), 58.7 (d, JF = 5.8 Hz), 55.4, 43.9. m/z
[EI (+ve)] 297.1 [M]+, HRMS found [M]+ 297.1169, C18H16FNO2
requires 297.1165. IR (thin film) vmax = 2933, 1707, 1666, 1512,
1247, 1174, 1030 cm−1. m.p. 101–103 °C.
1-Benzyl-3-fluoro-5-[(4′-trifluoromethyl)phenyl]-2,5-dihydro-
1H-pyrrol-2-one, 21b. Dialkene 20b (80 mg, 0.22 mmol) was
treated with 15 mol% Grubbs 2nd generation catalyst as
described in General procedure I. The crude product was puri-
fied by flash column chromatography (0–15% EtOAc in pet-
roleum ether) to yield the desired α,β-unsaturated lactam 21b
(70 mg, 0.20 mmol, 88%) as a pale yellow oil. 1H NMR (CDCl3,
400 MHz) δ: 7.58 (2H, d, JH = 8.1 Hz), 7.26–7.21 (3H, m), 7.16
(2H, d, JH = 8.1 Hz), 7.03–7.01 (2H, m), 6.19 (1H, d, JH =
1.2 Hz), 5.09 (1H, d, JH = 15.0 Hz), 4.77 (1H, dd, JF = 4.8 Hz,
JH = 2.0 Hz), 3.57 (1H, d, JH = 15.0 Hz).
19F NMR (CDCl3,
470 MHz) δ: −62.9, −137.2. 13C NMR (CDCl3, 125 MHz) δ:
162.9 (d, JF = 31.2 Hz), 152.7 (d, JF = 280.9 Hz), 138.1, 136.1,
131.7, 131.4, 129.0 (2C), 128.4 (2C),128.1, 128.0 (2C), 126.3 (2C,
q, JF = 3.7 Hz), 118.0 (d, JF = 5.0 Hz), 58.7 (d, JF = 5.7 Hz), 44.4.
m/z [EI (+ve)] 335.0 [M]+, HRMS found [M]+ 335.0932,
C18H13F4NO requires 335.0933. IR (thin film) vmax = 2362,
2332, 1718, 1670, 1421, 1325, 1166, 1126, 1066 cm−1.
1-Benzyl-3-fluoro-5-(4′-bromophenyl)-2,5-dihydro-1H-pyrrol-
2-one, 21c. Dialkene 20c (100 mg, 0.3 mmol) was treated with
10 mol% Grubbs 2nd generation catalyst as described in
General procedure I. The crude product was purified by flash
column chromatography (0–10% EtOAc in petroleum ether) to
yield the desired α,β-unsaturated lactam 21c (90 mg, 0.3 mmol,
94%) as a pale yellow oil. 1H NMR (CDCl3, 400 MHz) δ: 7.54
Paper Organic & Biomolecular Chemistry
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(2H, d, JH = 8.4 Hz), 7.36–7.30 (3H, m), 7.13–7.10 (2H, m), 7.00
(2H, d, JH = 8.4 Hz), 6.26 (1H, d, JH = 1.6 Hz), 5.17 (1H, d, JH =
15.0 Hz), 4.76 (1H, dd, JF = 5.8 Hz, JH = 2.2 Hz), 3.62 (1H, d,
JH = 15.0 Hz).
19F NMR (CDCl3, 470 MHz) δ: −137.7. 13C NMR
(CDCl3, 125 MHz) δ: 162.9 (d, JF = 31.2 Hz), 152.5 (d, JF =
280.5 Hz), 136.3, 132.9 (d, JF = 2.2 Hz), 132.5 (2C), 129.2 (2C),
128.9 (2C), 128.4 (2C), 128.0, 123.2, 118.1 (d, JF = 4.7 Hz), 58.6
(d, JF = 5.7 Hz), 44.2. m/z [EI (+ve)] 345.1 [M]
+, HRMS found
[M]+ 345.0165, C17H13BrFNO requires 345.0165. IR (thin film)
vmax = 3030, 1708, 1666, 1489, 1408, 1220, 1078, 1010 cm
−1.
1-Benzyl-3-fluoro-5-cyclohexyl-2,5-dihydro-1H-pyrrol-2-one,
21d. Dialkene 20d (100 mg, 0.34 mmol) was treated with
7.5 mol% Grubbs 2nd generation catalyst as described in
General procedure I. The crude product was purified by flash
column chromatography (0–5% EtOAc in petroleum ether) to
yield the desired α,β-unsaturated lactam 21d (90 mg,
0.32 mmol, 95%) as a white solid. 1H NMR (CDCl3, 400 MHz)
δ: 7.28–7.16 (5H, m), 6.12 (1H, d, JH = 2.1 Hz), 5.03 (1H, d, JH =
15.2 Hz), 4.01 (1H, d, JH = 15.2 Hz), 3.72–3.70 (1H, m),
1.83–1.69 (2H, m), 1.66–1.54 (3H, m), 1.31–1.18 (2H, m),
1.05–0.97 (3H, m), 0.87–0.77 (1H, m). 19F NMR (CDCl3,
470 MHz) δ: −136.9. 13C NMR (CDCl3, 125 MHz) δ: 163.4 (d,
JF = 31.5 Hz), 152.8 (d, JF = 277.4 Hz), 136.7, 128.3 (2C), 128.0
(2C), 127.7, 115.6 (d, JF = 4.2 Hz), 60.1 (d, JF = 4.4 Hz), 44.2,
37.8, 30.1, 36.5, 26.3, 25.7, 25.5. m/z [EI (+ve)] 273.2 [M]+,
HRMS found [M]+ 273.1527, C17H20FNO requires 273.1529. IR
(thin film) vmax = 2928, 2854, 1703, 1666, 1450, 1421, 1240,
1145 cm−1. m.p. 53–55 °C.
1-Benzyl-3-fluoro-5-(2′-phenylethyl)-2,5-dihydro-1H-pyrrol-2-
one, 21e. Dialkene 20e (120 mg, 0.38 mmol) was treated with
5 mol% Grubbs 2nd generation catalyst as described in General
procedure I. The crude product was purified by flash column
chromatography (0–10% EtOAc in petroleum ether) to yield the
desired α,β-unsaturated lactam 21e (110 mg, 0.36 mmol, 96%)
as a white solid. 1H NMR (CDCl3, 400 MHz) δ: 7.26–7.11 (8H,
m), 6.97–6.96 (2H, m), 6.17 (1H, d, JH = 1.6 Hz), 5.00 (1H, d,
JH = 15.2 Hz), 4.06 (1H, d, JH = 15.2 Hz), 3.88–3.85 (1H, m),
2.49–2.31 (2H, m), 2.11–2.04 (1H, m), 1.86–1.75 (1H, m). 19F
NMR (CDCl3, 470 MHz) δ: −137.0. 13C NMR (CDCl3, 125 MHz)
δ: 163.1 (d, JF = 31.3 Hz), 152.7 (d, JF = 278.2 Hz), 140.4, 136.5,
128.9 (2C), 128.7 (2C), 128.2 (2C), 128.1 (2C), 127.9, 126.4,
117.2 (d, JF = 4.2 Hz), 55.0 (d, JF = 5.0 Hz), 44.3, 31.7 (d, JF =
2.0 Hz), 30.0. m/z [EI (+ve)] 295.2 [M]+, HRMS found [M]+
295.1373, C19H18FNO requires 295.1372. IR (thin film) vmax =
2935, 2364, 1707, 1666, 1454, 1226 cm−1. m.p. 62–65 °C.
1-Benzyl-3-fluoro-5-(4′-methoxyphenyl)-2-methyl-1H-pyrrole,
22a. α,β-Unsaturated lactam 21a (32 mg, 0.11 mmol) was
reacted with methyllithium (83 μL, 1.2 mmol, 1.4 M in diethyl
ether) following General procedure II. The product was puri-
fied by flash column chromatography (0–2.5% diethyl ether in
petroleum ether) to yield the pyrrole 22a (28 mg, 0.09 mmol,
88%) as a white solid. 1H NMR (CDCl3, 400 MHz) δ: 7.25–7.16
(3H, m), 7.10 (2H, d, JH = 8.9 Hz), 6.86–6.84 (2H, m), 6.76 (2H,
d, JH = 8.9 Hz), 5.91 (1H, s), 4.95 (2H, s), 3.71 (3H, s), 1.97 (3H,
d, JF = 1.6 Hz).
19F NMR (CDCl3, 470 MHz) δ: −169.6. 13C NMR
(CDCl3, 125 MHz) δ: 158.9, 149.1 (d, JF = 235.4 Hz), 138.7,
130.2 (2C), 129.9 (d, JF = 3.3 Hz), 128.8 (2C), 127.1, 125.6 (2C),
125.4 (d, JF = 1.6 Hz), 113.9 (2C), 111.8 (d, JF = 24.4 Hz), 96.0
(d, JF = 16.4 Hz), 55.3, 47.6, 8.1 (d, JF = 2.0 Hz). m/z [EI (+ve)]
295.2 [M]+, HRMS found [M]+ 295.1373, C19H18FNO requires
295.1372. IR (thin film) vmax = 2929, 1653, 1603, 1454, 1249,
1176 cm−1. m.p. 74–76 °C.
1-Benzyl-3-fluoro-2-methyl-5-[(4′-trifluoromethyl)phenyl]-1H-
pyrrole, 22b. α,β-Unsaturated lactam 21b (22 mg, 0.06 mmol)
was reacted with methyllithium (51 μL, 0.07 mmol, 1.4 M in
diethyl ether) following General procedure II. The product was
purified by flash column chromatography (0–2.5% diethyl
ether in petroleum ether) to yield the pyrrole 22b (16 mg,
0.05 mmol, 73%) as a yellow solid. 1H NMR (CDCl3, 400 MHz)
δ: 7.46 (2H, d, JH = 8.7 Hz), 7.32–7.17 (5H, m), 6.87–6.85 (2H,
m), 6.05 (1H, s), 5.01 (2H, s), 2.00 (3H, d, JF = 1.6 Hz).
19F NMR
(CDCl3, 470 MHz) δ: −62.5, −168.5. 13C NMR (CDCl3,
125 MHz) δ: 149.3 (d, JF = 236.4 Hz), 138.1, 136.3, 129.0, 128.9
(2C), 128.6 (d, JF = 7.2 Hz), 128.5 (2C), 127.4, 126.0 (d, JF =
3.8 Hz), 125.5, 125.4 (2C), 114.1 (d, JF = 24.4 Hz), 96.7 (d, JF =
16.5 Hz), 47.9, 8.2 (d, JF = 2.0 Hz). m/z [EI (+ve)] 333.2 [M]
+,
HRMS found [M]+ 333.1139, C19H15F4N requires 333.1141. IR
(thin film) vmax = 2926, 1606, 1325, 1166, 1124 cm
−1. m.p.
75–77 °C.
1-Benzyl-5-(4′-bromophenyl)-3-fluoro-2-methyl-1H-pyrrole,
22c. α,β-Unsaturated lactam 21c (43 mg, 0.13 mmol) was
reacted with methyllithium (98 μL, 0.14 mmol, 1.4 M in
diethyl ether) following General procedure II. The product was
purified by flash column chromatography (0–2.5% diethyl
ether in petroleum ether) to yield the pyrrole 22c (34 mg,
0.10 mmol, 78%) as a brown solid. 1H NMR (CDCl3, 400 MHz)
δ: 7.37 (2H, d, JH = 8.6 Hz), 7.29–7.16 (3H, m), 7.04 (2H, d, JH =
8.6 Hz), 6.85–6.83 (2H, m), 5.97 (1H, s), 4.96 (2H, s), 1.98 (3H,
d, JF = 1.6 Hz).
19F NMR (CDCl3, 470 MHz) δ: −168.9. 13C NMR
(CDCl3, 125 MHz) δ: 149.2 (d, JF = 236.1 Hz), 138.3, 131.7 (d,
JF = 1.8 Hz), 131.6 (2C), 130.2 (2C), 128.9 (2C), 128.8, 127.3,
125.5 (2C), 121.2, 113.2 (d, JF = 24.3 Hz), 96.9 (d, JF = 16.5 Hz),
47.7, 8.2 (d, JF = 2.0 Hz). m/z [EI (+ve)] 343.1 [M]
+, HRMS found
[M]+ 343.0368, C18H15BrFN requires 343.0372. IR (thin film)
vmax = 2922, 1683, 1612, 1471, 1352 cm
−1. m.p. 98–100 °C.
1-Benzyl-5-cyclohexyl-3-fluoro-2-methyl-1H-pyrrole, 22d.
α,β-Unsaturated lactam 21d (32 mg, 0.12 mmol) was reacted
with methyllithium (92 μL, 0.13 mmol, 1.4 M in diethyl ether)
following General procedure II. The product was purified by
flash column chromatography (0–2.5% diethyl ether in pet-
roleum ether) to yield the pyrrole 22d (29 mg, 0.11 mmol,
92%) as a white solid. 1H NMR (CDCl3, 400 MHz) δ: 7.25–7.13
(3H, m), 6.80–6.76 (2H, m), 5.64 (1H, s), 4.90 (2H, s), 2.33–2.24
(1H, m), 1.91 (3H, d, JF = 1.6 Hz), 1.74–1.63 (4H, m), 1.26–1.08
(6H, m). 19F NMR (CDCl3, 470 MHz) δ: −170.6. 13C NMR
(CDCl3, 125 MHz) δ: 148.6 (d, JF = 233.9 Hz), 138.7, 134.8 (d,
JF = 5.7 Hz), 128.7 (2C), 127.1, 125.5 (2C), 109.3 (d, JF =
24.7 Hz), 91.8 (d, JF = 16.8 Hz), 46.4, 35.6, 34.1 (2C), 26.6 (2C),
26.0, 7.8 (d, JF = 2.1 Hz). m/z [EI (+ve)] 271.1 [M]
+, HRMS found
[M]+ 271.1737, C18H22FN requires 271.1736. IR (thin film) vmax
= 2926, 2852, 1616, 1446, 1365, 1348, 1112 cm−1. m.p.
55–57 °C.
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1-Benzyl-3-fluoro-2-methyl-5-(2′-phenylethyl)-1H-pyrrole, 22e.
α,β-Unsaturated lactam 21e (34 mg, 0.11 mmol) was reacted
with methyllithium (91 μL, 0.12 mmol, 1.4 M in diethyl ether)
following General procedure II. The product was purified by
flash column chromatography (0–2.5% diethyl ether in pet-
roleum ether) to yield the pyrrole 22e (24 mg, 0.08 mmol, 74%)
as a yellow oil. 1H NMR (CDCl3, 400 MHz) δ: 7.24–7.08 (6H, m),
7.04–7.00 (2H, m), 6.80–6.76 (2H, m), 5.71 (1H, s), 4.83 (2H, s),
2.76–2.71 (2H, m), 2.64–2.60 (2H, m), 1.97 (3H, br s). 19F NMR
(CDCl3, 470 MHz) δ: −170.5. 13C NMR (CDCl3, 125 MHz)
δ: 148.3 (d, JF = 234.1 Hz), 141.4, 138.2, 128.8 (2C), 128.4 (2C),
128.3 (2C), 127.9 (d, JF = 6.3 Hz), 127.2, 126.1, 125.5 (2C), 110.0
(d, JF = 24.6 Hz), 94.1 (d, JF = 16.8 Hz), 46.5, 35.4, 28.4, 7.9 (d,
JF = 2.1 Hz). m/z [EI (+ve)] 293.1 [M]
+, HRMS found [M]+
293.1581, C20H20FN requires 293.1580. IR (thin film) vmax =
2922, 1614, 1496, 1454, 1417, 1363, 1114 cm−1.
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